Literature DB >> 12095278

DNA methylation and epigenetic inheritance.

Robin Holliday1, Thu Ho.   

Abstract

Mammalian cell lines silence genes at low frequency by the methylation of promoter sequences. These silent genes can be reactivated at high frequency by the demethylating agent 5-azacytidine (5-aza-CR). The inactive and active epigenetic states of such genes are stably inherited. A method for silencing genes is now available. It involves treatment of permeabilized cells with 5-methyl deoxycytidine triphosphate (5-methyl dCTP) which is incorporated into DNA. The methylation of promoter sequences has been confirmed using the bisulfite genomic sequencing procedure. Methylated oligonucleotides homologous to promoter sequences might be used to specifically target and silence given genes, but results so far have not been conclusive. Treatments that silence or reactivate genes by changing DNA methylation can be referred to as epimutagens, as distinct from mutagens that act by changing DNA sequences. The epimutagen 5-aza-CR reactivates genes but has little mutagenic activity, whereas standard mutagens (such as ethyl methane sulfonate and ultraviolet light) have little reactivation activity. Nevertheless, much more information is required about the effects of DNA-damaging agents in changing DNA methylation and gene activity and also about the role of epimutations in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095278     DOI: 10.1016/s1046-2023(02)00072-5

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  15 in total

Review 1.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases.

Authors:  Shuk-mei Ho; Wan-yee Tang
Journal:  Reprod Toxicol       Date:  2007-01-19       Impact factor: 3.143

2.  High rate of mutation reporter gene inactivation during human T cell proliferation.

Authors:  Aida Gabdoulkhakova; Gunnel Henriksson; Nadezhda Avkhacheva; Alexander Sofin; Anders Bredberg
Journal:  Immunogenetics       Date:  2006-12-19       Impact factor: 2.846

3.  Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns.

Authors:  Victoria Valinluck Lao; Jason L Herring; Cherine H Kim; Agus Darwanto; Ubaldo Soto; Lawrence C Sowers
Journal:  Carcinogenesis       Date:  2009-03-11       Impact factor: 4.944

Review 4.  Sex differences in the developmental origins of hypertension and cardiorenal disease.

Authors:  Jeffrey S Gilbert; Mark J Nijland
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-29       Impact factor: 3.619

5.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2).

Authors:  Victoria Valinluck; Hsin-Hao Tsai; Daniel K Rogstad; Artur Burdzy; Adrian Bird; Lawrence C Sowers
Journal:  Nucleic Acids Res       Date:  2004-08-09       Impact factor: 16.971

6.  Establishment of a high-throughput detection system for DNA demethylating agents.

Authors:  Eriko Okochi-Takada; Naoko Hattori; Akihiro Ito; Tohru Niwa; Mika Wakabayashi; Kana Kimura; Minoru Yoshida; Toshikazu Ushijima
Journal:  Epigenetics       Date:  2018-03-05       Impact factor: 4.528

7.  Cytostatic drug treatment causes seeding of gene promoter methylation.

Authors:  Anders Bredberg; Walter Bodmer
Journal:  Eur J Cancer       Date:  2007-01-22       Impact factor: 9.162

8.  Maternal cocaine administration in mice alters DNA methylation and gene expression in hippocampal neurons of neonatal and prepubertal offspring.

Authors:  Svetlana I Novikova; Fang He; Jie Bai; Nicholas J Cutrufello; Michael S Lidow; Ashiwel S Undieh
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

9.  Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells.

Authors:  Masataka Ushijima; Yutaka Ogata; Hideaki Tsuda; Yoshito Akagi; Keiko Matono; Kazuo Shirouzu
Journal:  Oncol Rep       Date:  2013-11-08       Impact factor: 3.906

10.  A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.

Authors:  Julie Bauman; Monte Shaheen; Claire F Verschraegen; Steven A Belinsky; M Houman Fekrazad; Fa-Chyi Lee; Ian Rabinowitz; Meera Ravindranathan; Dennie V Jones
Journal:  Transl Oncol       Date:  2014-04-17       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.